COPENHAGEN, March 18 Denmark's Novo Nordisk
, the world's biggest insulin producer, said on Monday
sufferers of Type 2 diabetes achieved 6 percent weight loss with
one of their obesity drugs in a trial.
Novo Nordisk said subjects with Type 2 diabetes achieved 6
percent weight loss with 3 milligrams of liraglutide in the
advanced Phase III trial, compared to 2 percent for people who
were given a placebo.
"We are pleased about the outcome of this trial and look
forward to getting the results from the two remaining trials in
the SCALE programme", said Mads Krogsgaard Thomsen, chief
science officer at Novo Nordisk.
The company expects to complete the two remaining Phase III
trials in the programme by mid-2013.
(Reporting by Johan Ahlander; Editing by Greg Mahlich)